Biocryst Pharmaceuticals (BCRX) Interest Coverage Ratio (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Interest Coverage Ratio of 9.88 for Q1 2026, down 153.64% on a QoQ basis from 18.42 in Q4 2025, and down 1193.55% year-over-year from 0.9 in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Interest Coverage Ratio (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Interest Coverage Ratio history runs 16 years deep, the most recent figure standing at 9.88 for Q1 2026.
- Quarterly Interest Coverage Ratio fell 1193.55% year-over-year to 9.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.38 (down 2553.06% YoY) and the FY2025 annual result came in at 0.9, up 15912.93% from the prior year.
- Interest Coverage Ratio was 9.88 for Q1 2026 at Biocryst Pharmaceuticals, down from 18.42 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 18.42 in Q4 2025 and bottomed at 9.88 in Q1 2026.
- A 5-year average of 0.19 and a median of 0.47 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2025 — Interest Coverage Ratio soared 32085.55% — and 2026, when it sank 1193.55%.
- Biocryst Pharmaceuticals' Interest Coverage Ratio stood at 1.75 in 2022, then soared by 73.18% to 0.47 in 2023, then jumped by 87.73% to 0.06 in 2024, then soared by 32085.55% to 18.42 in 2025, then sank by 153.64% to 9.88 in 2026.
- Business Quant data shows BCRX's Interest Coverage Ratio at 9.88 in Q1 2026, 18.42 in Q4 2025, and 1.02 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -9.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.88 |
| Dec 31, 2025 | 18.42 |
| Sep 30, 2025 | 1.02 |
| Jun 30, 2025 | 1.38 |
| Mar 31, 2025 | 0.90 |
| Dec 31, 2024 | -0.06 |
| Sep 30, 2024 | 0.31 |
| Jun 30, 2024 | 0.35 |
| Mar 31, 2024 | -0.59 |
| Dec 31, 2023 | -0.47 |
| Sep 30, 2023 | -0.44 |
| Jun 30, 2023 | -0.72 |
| Mar 31, 2023 | -1.04 |
| Dec 31, 2022 | -1.75 |
| Sep 30, 2022 | -0.70 |
| Jun 30, 2022 | -1.45 |
| Mar 31, 2022 | -2.10 |
| Dec 31, 2021 | 1.34 |
| Sep 30, 2021 | -3.16 |
| Jun 30, 2021 | -2.19 |